Bristol Myers’ Abecma wins FDA nod in earlier multiple myeloma with updated boxed warning on secondary cancer
Fierce Pharma
APRIL 5, 2024
After a short period of doubt, the FDA has followed the opinion of its advisers and moved Bristol Myers Squibb’s CAR-T therapy Abecma into the earlier treatment of multiple myeloma. The new nod also comes with an updated boxed warning and a wider dosing range.
278 
Let's personalize your content